Spexis Publishes Invitation to Annual General Meeting 2022

ByLois C

Apr 5, 2022 , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,

Advert hoc announcement pursuant to Artwork. 53 LR

    &#13

  • Pre-AGM facts phone on April 7, 2022 at 2:30PM CET
  • &#13

  • AGM to be held April 26, 2022
  • &#13

  • Shareholders not physically existing, in accordance with COVID-19 ordinances
  • &#13

ALLSCHWIL, SWITZERLAND / ACCESSWIRE / April 1, 2022 / Spexis AG (6:SPEX) a clinical-stage biopharmaceutical corporation, concentrated on rare disorders and oncology with an first concentration on chronic respiratory health conditions right now released the invitation to its Yearly Common Assembly on April 26, 2022.

As a precautionary and prudent evaluate, the Board of Administrators has made the decision to conduct the Yearly Normal Conference 2022 without the need of the actual physical presence of shareholders, in accordance with Article 8 of the Federal Act on the Statutory Concepts for Federal Council Ordinances on Combating the COVID-19 Epidemic (COVID-19 Act) and Short article 27 of Ordinance 3 on Steps to Battle the Coronavirus (COVID-19) (COVID-19 Ordinance 3).

The business will be in search of to optimize the amount of shareholders executing their voting legal rights and will host a pre-AGM details simply call on April 7, 2022 at 2:30PM CET. Traders are invited to post thoughts in progress by e mail to [email protected] To accessibility the earnings simply call, please use the subsequent facts:

France: +33 ()1 70 730 3 39
&#13
Germany: +49 ()69 22222 5197
&#13
Italy: +39 02 3602 6066
&#13
Switzerland +41 ()44 580 7279
&#13
United Kingdom +44 ()330 165 4012
&#13
United States +1 646-828-8073

Party Title: Spexis AG – Once-a-year Standard Meeting Data Contact 2022

Affirmation code: 3315627

The presentation will also be obtainable by means of webcast: https://www.webcast-eqs.com/spexis20220407/no-audio
&#13
Connection for individuals of the meeting connect with (only slides, no audio, no hold off): https://www.webcast-eqs.com/spexis20220407/no-audio

Following the call, the presentation will be accessible by using the above connection.

For additional information please make contact with:

For Buyers:

Hernan Levett
&#13
Chief Economic Officer
&#13
Spexis AG.
&#13
+41 61 567 16 00
&#13
[email protected]

For Media:

Dr. Stephan Feldhaus
&#13
Feldhaus & Husband or wife
&#13
+41 79 865 92 56
&#13
[email protected]

About Spexis

Spexis is a clinical-phase biopharmaceutical firm dependent in Allschwil, Switzerland, focused on rare health conditions and oncology. The existing pipeline of the corporation is a blend of two legacy providers, Polyphor AG and EnBiotix, Inc. (Boston, MA, United states) which merged in December 2021. The combined company has been renamed to Spexis AG and is investing on the Six Swiss Trade below the symbol Six:SPEX. For even further information make sure you go to: www.spexisbio.com.

Disclaimer

This press launch contains forward-hunting statements which are dependent on present-day assumptions and forecasts of Spexis administration. Regarded and mysterious hazards, uncertainties, and other components could direct to content discrepancies in between the forward-on the lookout statements built listed here and the actual enhancement, in unique Spexis’ results, money situation, and functionality. Viewers are cautioned not to set undue reliance on forward-on the lookout statements, which talk only of the day of this interaction. Spexis disclaims any intention or obligation to update and revise any ahead-hunting statements, no matter if as a final result of new details, long run functions or otherwise.

Source: Polyphor AG

&#13
Watch supply variation on accesswire.com:
&#13
https://www.accesswire.com/695618/Spexis-Publishes-Invitation-to-Once-a-year-Typical-Assembly-2022

By Lois C